Plain English Breakdown
The source does not define exactly which entities are 'specified' to participate; it refers to them generally without a list.
California Investigational Peptide and Novel Compound Research Program
This law creates a state program that allows approved groups to test, study, and provide access to certain experimental medicines called peptides while setting safety rules.
What This Bill Does
- Creates the California Investigational Peptide and Novel Compound Research and Therapeutic Access Program for specified entities.
- Allows participating groups to conduct independent batch testing on peptide and novel compounds as defined by the bill.
- Requires participants to follow certain manufacturing standards and keep chain-of-custody records for all compounds.
- Mandates that each participant form an oversight committee with specific members to review safety issues.
- Permits licensed health care practitioners acting within their scope of practice to prescribe or dispense investigational therapeutic compounds if they meet program requirements.
- Protects entities, doctors, pharmacists, manufacturers, and researchers from civil lawsuits for actions taken in good faith under this law.
Who It Names or Affects
- Specified entities that choose to join the research and therapeutic access program.
- Licensed health care practitioners who prescribe or dispense investigational compounds within their scope of practice.
- Pharmacists, manufacturers, and researchers involved with these specific compounds.
- The State Department of Public Health, which receives reports from participants.
Terms To Know
- Peptides
- Specific compounds defined by the bill that are used for research or treatment under this program.
- Investigational therapeutic compound
- A medicine or substance being studied and prescribed under specific requirements set by this law.
- Chain-of-custody documentation
- Written records required to track the handling of compounds as specified in the bill.
Limits and Unknowns
- The main program rules and protections end on January 1, 2037.
- A separate working group must submit recommendations to the Legislature by January 1, 2029, but those provisions expire on January 1, 2030.
- The bill does not list exactly which entities are eligible without referring to other unspecified details.